Comparison of intravitreal bevacizumab versus triamcinolone for the treatment of diffuse diabetic macular edema

Ophthalmologica

Volumn 224, Issue 4, 2010, Pages 258-264

  Kreutzer, Thomas C ^a   Al Saeidi, Rashid ^a   Kook, Daniel ^a   Wolf, Armin ^a   Ulbig, Michael W ^a   Neubauer, Aljoscha S ^a   Haritoglou, Christos ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bevacizumab; Diabetic macular edema; Triamcinolone

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE; ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; DIABETIC MACULAR EDEMA; DRUG EFFECT; FEMALE; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PREOPERATIVE PERIOD; RETINA; SINGLE DRUG DOSE; THICKNESS; TREATMENT OUTCOME; VISUAL ACUITY; AGED; COMPARATIVE STUDY; COMPLICATION; DIABETIC RETINOPATHY; DRUG EFFECTS; FOLLOW UP; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; PHYSIOLOGY; PROCEDURES; RADIOGRAPHY; RETROSPECTIVE STUDY;

AGED; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENTRICULAR; MACULAR EDEMA; MALE; MIDDLE AGED; RETINA; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, OPTICAL COHERENCE; TRIAMCINOLONE; VISUAL ACUITY; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 76549110743     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000284466     Document Type: Article

References (32)

1. Harris MI: Diabetes in America: epidemiology and scope of the problem. Diabetes Care 1998; 21(suppl 3):C11-C14.
2. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, Yeo KT: Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445-450.
3. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP: A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004; 18: 1450-1452. (Pubitemid 39561611)
4. Audren F, Erginay A, Haouchine B, Benosman R, Conrath J, Bergmann JF, Gaudric A, Massin P: Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand 2006; 84: 624-630. (Pubitemid 44317541)
5. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ: Intravitreal bevacizumab (avastin) for neovascular agerelated macular degeneration. Ophthalmology 2006; 113: 363-372, e365.
6. Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT, Emerson GG, Schlesinger TK, Nolte SK, Klein ML: Intravitreal bevacizumab (avastin) treatment of neovascular age-related macular degeneration. Retina 2007; 27: 439-444.
7. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A: Intravitreal bevacizumab (avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26: 999-1005.
8. Priglinger SG, Wolf AH, Kreutzer TC, Kook D, Hofer A, Strauss RW, Alge CS, Kunze C, Haritoglou C, Kampik A: Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 2007; 27: 1004-1012.
9. Patz A, Schatz H, Berkow JW, Gittelsohn AM, Ticho U: Macular edema - an overlooked complication of diabetic retinopathy. Trans Am Acad Ophthalmol Otolaryngol 1973; 77:OP34-OP42.
10. Early Treatment Diabetic Retinopathy Study Research Group: Focal photocoagulation treatment of diabetic macular edema: relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report No 19. Arch Ophthalmol 1995; 113: 1144-1155.
11. Audren F, Lecleire-Collet A, Erginay A, Haouchine B, Benosman R, Bergmann JF, Gaudric A, Massin P: Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol 2006; 142: 794-799.
12. Brasil OF, Smith SD, Galor A, Lowder CY, Sears JE, Kaiser PK: Predictive factors for short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema: an optical coherence tomography study. Br J Ophthalmol 2007; 91: 761-765.
13. Gibran SK, Cullinane A, Jungkim S, Cleary PE: Intravitreal triamcinolone for diffuse diabetic macular oedema. Eye 2006; 20: 720-724.
14. Jonas JB, Akkoyun I, Kreissig I, Degenring RF: Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study. Br J Ophthalmol 2005; 89: 321-326. (Pubitemid 40327617)
15. Jonas JB, Kamppeter BA, Harder B, Vossmerbaeumer U, Sauder G, Spandau UH: Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 2006; 22: 200-207. (Pubitemid 44051133)
16. Matsuda S, Gomi F, Oshima Y, Tohyama M, Tano Y: Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress. Invest Ophthalmol Vis Sci 2005; 46: 1062-1068.
17. Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC: Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes 2008; 57: 1026-1033.
18. Thompson JT: Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol 2006; 141: 629-637.
19. Ferrara N, Hillan KJ, Novotny W: Bevacizumab (avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333: 328-335.
20. Ishizaki E, Takai S, Ueki M, Maeno T, Maruichi M, Sugiyama T, Oku H, Ikeda T, Miyazaki M: Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy. Am J Ophthalmol 2006; 141: 129-134.
21. Kakehashi A, Inoda S, Mameuda C, Kuroki M, Jono T, Nagai R, Horiuchi S, Kawakami M, Kanazawa Y: Relationship among VEGF, VEGF receptor, AGEs, and macrophages in proliferative diabetic retinopathy. Diabetes Res Clin Pract 2007; 79: 438-445.
22. Mason JO 3rd, Nixon PA, White MF: Intravitreal injection of bevacizumab (avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142: 685-688.
23. Mysliwiec M, Balcerska A, Zorena K, Mysliwska J, Lipowski P, Raczynska K: The role of vascular endothelial growth factor, tumor necrosis factor- and interleukin-6 in pathogenesis of diabetic retinopathy. Diabetes Res Clin Pract 2008; 79: 141-146.
24. Sawada O, Kawamura H, Kakinoki M, Sawada T, Ohji M: Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol 2007; 125: 1363-1366.
25. Starita C, Patel M, Katz B, Adamis AP: Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy. Dev Ophthalmol 2007; 39: 122-148.
26. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, Berrocal MH, Solis-Vivanco A, Farah ME: Primary intravitreal bevacizumab (avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007; 114: 743-750. (Pubitemid 46483714)
27. Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD: A phase II randomized doublemasked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112: 1747-1757.
28. Soheilian M, Ramezani A, Bijanzadeh B, Yaseri M, Ahmadieh H, Dehghan MH, Azarmina M, Moradian S, Tabatabaei H, Peyman GA: Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 2007; 27: 1187-1195.
29. Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR: A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114: 1860-1867.
30. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA: Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005; 112: 593-598. (Pubitemid 41108858)
31. La Heij EC, Lundqvist IJ, Berendschot TT, Hardy E, Liem AT, Hendrikse F: Intravitreal prednisolone sodium succinate reduces diabetic macular edema without intraocular pressure rise. Am J Ophthalmol 2007; 143: 176-178.
32. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115: 1447-1449, 1449. e1-10.